414 related articles for article (PubMed ID: 30297712)
21. SMARCA4/2 loss inhibits chemotherapy-induced apoptosis by restricting IP3R3-mediated Ca
Xue Y; Morris JL; Yang K; Fu Z; Zhu X; Johnson F; Meehan B; Witkowski L; Yasmeen A; Golenar T; Coatham M; Morin G; Monast A; Pilon V; Fiset PO; Jung S; Gonzalez AV; Camilleri-Broet S; Fu L; Postovit LM; Spicer J; Gotlieb WH; Guiot MC; Rak J; Park M; Lockwood W; Foulkes WD; Prudent J; Huang S
Nat Commun; 2021 Sep; 12(1):5404. PubMed ID: 34518526
[TBL] [Abstract][Full Text] [Related]
22. ARID1A mutant ovarian clear cell carcinoma: A clear target for synthetic lethal strategies.
Caumanns JJ; Wisman GBA; Berns K; van der Zee AGJ; de Jong S
Biochim Biophys Acta Rev Cancer; 2018 Dec; 1870(2):176-184. PubMed ID: 30025943
[TBL] [Abstract][Full Text] [Related]
23. ARID1A-mutated ovarian cancers depend on HDAC6 activity.
Bitler BG; Wu S; Park PH; Hai Y; Aird KM; Wang Y; Zhai Y; Kossenkov AV; Vara-Ailor A; Rauscher FJ; Zou W; Speicher DW; Huntsman DG; Conejo-Garcia JR; Cho KR; Christianson DW; Zhang R
Nat Cell Biol; 2017 Aug; 19(8):962-973. PubMed ID: 28737768
[TBL] [Abstract][Full Text] [Related]
24. Frequent co-inactivation of the SWI/SNF subunits SMARCB1, SMARCA2 and PBRM1 in malignant rhabdoid tumours.
Rao Q; Xia QY; Wang ZY; Li L; Shen Q; Shi SS; Wang X; Liu B; Wang YF; Shi QL; Ma HH; Lu ZF; He Y; Zhang RS; Yu B; Zhou XJ
Histopathology; 2015 Jul; 67(1):121-9. PubMed ID: 25496315
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of EZH2 by chemo- and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancer.
Wu C; Jin X; Yang J; Yang Y; He Y; Ding L; Pan Y; Chen S; Jiang J; Huang H
Oncotarget; 2016 Jan; 7(3):3440-52. PubMed ID: 26657505
[TBL] [Abstract][Full Text] [Related]
26. Potential therapeutic targets in ARID1A-mutated cancers.
Bitler BG; Fatkhutdinov N; Zhang R
Expert Opin Ther Targets; 2015; 19(11):1419-22. PubMed ID: 26125128
[TBL] [Abstract][Full Text] [Related]
27. Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas.
Yamagishi M; Hori M; Fujikawa D; Ohsugi T; Honma D; Adachi N; Katano H; Hishima T; Kobayashi S; Nakano K; Nakashima M; Iwanaga M; Utsunomiya A; Tanaka Y; Okada S; Tsukasaki K; Tobinai K; Araki K; Watanabe T; Uchimaru K
Cell Rep; 2019 Nov; 29(8):2321-2337.e7. PubMed ID: 31747604
[TBL] [Abstract][Full Text] [Related]
28. ARID1A Hypermethylation Disrupts Transcriptional Homeostasis to Promote Squamous Cell Carcinoma Progression.
Luo Q; Wu X; Chang W; Zhao P; Zhu X; Chen H; Nan Y; Luo A; Zhou X; Su D; Jiao W; Liu Z
Cancer Res; 2020 Feb; 80(3):406-417. PubMed ID: 32015157
[TBL] [Abstract][Full Text] [Related]
29. Potential of enhancer of zeste homolog 2 inhibitors for the treatment of SWI/SNF mutant cancers and tumor microenvironment modulation.
Pyziak K; Sroka-Porada A; Rzymski T; Dulak J; Łoboda A
Drug Dev Res; 2021 Sep; 82(6):730-753. PubMed ID: 33565092
[TBL] [Abstract][Full Text] [Related]
30. Non-small cell lung cancer with loss of expression of the SWI/SNF complex is associated with aggressive clinicopathological features, PD-L1-positive status, and high tumor mutation burden.
Naito T; Udagawa H; Umemura S; Sakai T; Zenke Y; Kirita K; Matsumoto S; Yoh K; Niho S; Tsuboi M; Ishii G; Goto K
Lung Cancer; 2019 Dec; 138():35-42. PubMed ID: 31630044
[TBL] [Abstract][Full Text] [Related]
31. Switch/sucrose nonfermenting nucleosome complex-deficient colorectal carcinomas have distinct clinicopathologic features.
Villatoro TM; Ma C; Pai RK
Hum Pathol; 2020 May; 99():53-61. PubMed ID: 32222462
[TBL] [Abstract][Full Text] [Related]
32. NSD1 mediates antagonism between SWI/SNF and polycomb complexes and is required for transcriptional activation upon EZH2 inhibition.
Drosos Y; Myers JA; Xu B; Mathias KM; Beane EC; Radko-Juettner S; Mobley RJ; Larsen ME; Piccioni F; Ma X; Low J; Hansen BS; Peters ST; Bhanu NV; Dhanda SK; Chen T; Upadhyaya SA; Pruett-Miller SM; Root DE; Garcia BA; Partridge JF; Roberts CWM
Mol Cell; 2022 Jul; 82(13):2472-2489.e8. PubMed ID: 35537449
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of an EZH2 inhibitor in patient-derived orthotopic xenograft models of pediatric brain tumors alone and in combination with chemo- and radiation therapies.
Qi L; Lindsay H; Kogiso M; Du Y; Braun FK; Zhang H; Guo L; Zhao S; Injac SG; Baxter PA; Su JM; Xiao S; Erickson SW; Earley EJ; Teicher B; Smith MA; Li XN
Lab Invest; 2022 Feb; 102(2):185-193. PubMed ID: 34802040
[TBL] [Abstract][Full Text] [Related]
34. The spectrum of SWI/SNF mutations, ubiquitous in human cancers.
Shain AH; Pollack JR
PLoS One; 2013; 8(1):e55119. PubMed ID: 23355908
[TBL] [Abstract][Full Text] [Related]
35. EZH2-Mediated Downregulation of the Tumor Suppressor DAB2IP Maintains Ovarian Cancer Stem Cells.
Zong X; Wang W; Ozes A; Fang F; Sandusky GE; Nephew KP
Cancer Res; 2020 Oct; 80(20):4371-4385. PubMed ID: 32816909
[TBL] [Abstract][Full Text] [Related]
36. SWI/SNF Complexes in Ovarian Cancer: Mechanistic Insights and Therapeutic Implications.
Fukumoto T; Magno E; Zhang R
Mol Cancer Res; 2018 Dec; 16(12):1819-1825. PubMed ID: 30037854
[TBL] [Abstract][Full Text] [Related]
37. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma.
Huang HN; Lin MC; Huang WC; Chiang YC; Kuo KT
Mod Pathol; 2014 Jul; 27(7):983-90. PubMed ID: 24336158
[TBL] [Abstract][Full Text] [Related]
38. The clinicopathological significance of SWI/SNF alterations in gastric cancer is associated with the molecular subtypes.
Huang SC; Ng KF; Chang IY; Chang CJ; Chao YC; Chang SC; Chen MC; Yeh TS; Chen TC
PLoS One; 2021; 16(1):e0245356. PubMed ID: 33481850
[TBL] [Abstract][Full Text] [Related]
39. Chromatin accessibility underlies synthetic lethality of SWI/SNF subunits in ARID1A-mutant cancers.
Kelso TWR; Porter DK; Amaral ML; Shokhirev MN; Benner C; Hargreaves DC
Elife; 2017 Oct; 6():. PubMed ID: 28967863
[TBL] [Abstract][Full Text] [Related]
40. Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia.
Göllner S; Oellerich T; Agrawal-Singh S; Schenk T; Klein HU; Rohde C; Pabst C; Sauer T; Lerdrup M; Tavor S; Stölzel F; Herold S; Ehninger G; Köhler G; Pan KT; Urlaub H; Serve H; Dugas M; Spiekermann K; Vick B; Jeremias I; Berdel WE; Hansen K; Zelent A; Wickenhauser C; Müller LP; Thiede C; Müller-Tidow C
Nat Med; 2017 Jan; 23(1):69-78. PubMed ID: 27941792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
